Get the Stockscreener App
70.60
0.09%
0.06
Pre-market:
71.50
0.90
+1.27%
Biomarin Pharmaceutical Inc Stock (BMRN) Forecast
The Biomarin Pharmaceutical Inc (BMRN) stock price forecast for the next 30 days is generally positive, with an average analyst price target of $83.67, representing a +18.51% increase from the current price of $70.60. The highest analyst price target is $98.09, and the lowest is $69.24.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month BMRN Price Target
Average 101.09
(+43.19% Upside)
Is Biomarin Pharmaceutical Inc (BMRN) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 59.53 | Neutral |
| STOCH(9,6) | 54.77 | Neutral |
| STOCHRSI(14) | 2.924 | Buy |
| MACD(12,26) | 1.5904 | Sell |
| ADX(14) | 34.90 | Buy |
| William %R | -49.96 | Neutral |
| CCI(14) | 6.9206 | Neutral |
Buy: 2
Sell: 1
Neutral: 4
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
71.10
Sell
|
70.58
Buy
|
| MA20 |
69.29
Buy
|
69.38
Buy
|
| MA50 |
66.22
Buy
|
67.59
Buy
|
| MA100 |
66.31
Buy
|
68.51
Buy
|
| MA200 |
73.83
Sell
|
72.77
Sell
|
Buy: 7
Sell: 3
Neutral: 0
Summary: Buy
According to our latest analysis, BMRN could be considered a Strong Buy, with 17 technical analysis indicators signaling 9 Buy signals, 4 signaling Sell signals and 4 Neutral signals. This might be a good time to open fresh positions on BMRN, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 59.53 indicates that BMRN is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 54.77 indicates that BMRN is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 2.924 indicates that BMRN is oversold. This suggests that BMRN price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 34.9 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 6.9206 indicates that BMRN is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term BMRN price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Biomarin Pharmaceutical Inc financial reports and earnings history, Biomarin Pharmaceutical Inc (BMRN) stock could reach $92.39 by 2030, $103.38 by 2040 and $86.91 by 2050. See the projected annual prices until 2050 of the Biomarin Pharmaceutical Inc stock below:
- Biomarin Pharmaceutical Inc (BMRN) is expected to reach an average price of $90.20 in 2035, with a high prediction of $91.38 and a low estimate of $78.03. This indicates an $27.76% rise from the last recorded price of $70.60.
- Biomarin Pharmaceutical Inc (BMRN) stock is projected to chart a bullish course in 2040, with an average price target of $99.04, representing an $40.29% surge from its current level. The forecast ranges from a conservative $92.25 to a sky-high $103.38.
- Our analysts predict Biomarin Pharmaceutical Inc (BMRN) to jump 30.52% by 2045, soaring from $85.66 to an average price of $92.15, potentially reaching $96.06. While $85.66 is the low estimate, the potential upside is significant.
- Biomarin Pharmaceutical Inc (BMRN) stock is expected to climb by 2050, reaching an average of $86.66, a $22.75% jump from its current level. However, a wide range of estimates exists, with high and low targets of $86.91 and $78.75, respectively, highlighting the market's uncertainty.
Biomarin Pharmaceutical Inc Stock (BMRN) Year by Year Forecast
Biomarin Pharmaceutical Inc Stock (BMRN) Price Forecast for 2025
Biomarin Pharmaceutical Inc Stock (BMRN) is expected to reach an average price of $101.09 in 2025, with a high prediction of $132.94 and a low estimate of $69.24. This indicates an +43.19% rise from the last recorded price of $70.60.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| April, 2025 | $85.13 | $69.24 | $98.09 | +20.59% |
| May, 2025 | $93.86 | $79.76 | $95.33 | +32.95% |
| June, 2025 | $94.73 | $87.76 | $101.63 | +34.18% |
| July, 2025 | $124.59 | $93.43 | $125.94 | +76.48% |
| August, 2025 | $127.05 | $119.37 | $130.88 | +79.96% |
| September, 2025 | $119.66 | $118.71 | $132.94 | +69.50% |
| October, 2025 | $77.00 | $73.24 | $122.23 | +9.06% |
| November, 2025 | $77.08 | $72.35 | $81.94 | +9.17% |
| December, 2025 | $75.43 | $73.40 | $81.51 | +6.83% |
Biomarin Pharmaceutical Inc Stock (BMRN) Price Forecast for 2026
The predicted value for Biomarin Pharmaceutical Inc (BMRN) in 2026 is set at an average of $83.10. Estimates vary from a peak of $93.56 to a trough of $72.65, indicating an +17.71% surge from the present price of $70.60.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $81.40 | $72.65 | $81.65 | +15.29% |
| February, 2026 | $89.77 | $76.95 | $93.56 | +27.15% |
| March, 2026 | $83.97 | $80.51 | $93.20 | +18.93% |
| April, 2026 | $82.76 | $82.46 | $90.13 | +17.22% |
| May, 2026 | $79.18 | $75.53 | $85.52 | +12.15% |
| June, 2026 | $78.07 | $73.77 | $80.85 | +10.58% |
| July, 2026 | $77.93 | $75.43 | $82.75 | +10.38% |
| August, 2026 | $83.07 | $76.75 | $85.14 | +17.66% |
| September, 2026 | $84.62 | $81.14 | $87.33 | +19.85% |
| October, 2026 | $79.13 | $77.01 | $84.84 | +12.08% |
| November, 2026 | $85.21 | $74.95 | $86.01 | +20.69% |
| December, 2026 | $78.29 | $76.81 | $86.28 | +10.89% |
Biomarin Pharmaceutical Inc Stock (BMRN) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Biomarin Pharmaceutical Inc (BMRN) is $85.24, with a high forecast of $98.76 and a low forecast of $71.73. This indicates an +20.74% increase from the last price of $70.60.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $74.75 | $74.10 | $80.49 | +5.88% |
| February, 2027 | $92.47 | $72.59 | $92.72 | +30.97% |
| March, 2027 | $87.48 | $82.15 | $93.17 | +23.91% |
| April, 2027 | $91.22 | $83.00 | $92.74 | +29.20% |
| May, 2027 | $89.63 | $82.11 | $91.17 | +26.95% |
| June, 2027 | $77.32 | $73.00 | $95.20 | +9.52% |
| July, 2027 | $78.10 | $74.75 | $83.57 | +10.62% |
| August, 2027 | $81.50 | $77.76 | $87.59 | +15.44% |
| September, 2027 | $81.97 | $74.93 | $85.66 | +16.10% |
| October, 2027 | $77.08 | $71.73 | $81.45 | +9.18% |
| November, 2027 | $90.02 | $78.22 | $91.47 | +27.51% |
| December, 2027 | $96.07 | $85.33 | $98.76 | +36.08% |
Biomarin Pharmaceutical Inc Stock (BMRN) Price Forecast for 2028
In 2028, Biomarin Pharmaceutical Inc (BMRN) is projected to reach an average price of $100.15, with a high projection of $118.77 and a low estimate of $81.53. This indicates an +41.86% rise from the last price of $70.60.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $90.64 | $89.78 | $98.00 | +28.39% |
| February, 2028 | $85.77 | $82.66 | $94.23 | +21.49% |
| March, 2028 | $87.63 | $84.10 | $93.76 | +24.12% |
| April, 2028 | $97.92 | $81.53 | $100.74 | +38.70% |
| May, 2028 | $105.34 | $97.52 | $110.56 | +49.21% |
| June, 2028 | $111.75 | $101.52 | $115.80 | +58.29% |
| July, 2028 | $110.46 | $110.09 | $118.77 | +56.46% |
| August, 2028 | $91.49 | $90.39 | $110.65 | +29.59% |
| September, 2028 | $100.60 | $88.34 | $100.80 | +42.49% |
| October, 2028 | $97.63 | $90.25 | $101.38 | +38.29% |
| November, 2028 | $94.36 | $86.66 | $98.50 | +33.66% |
| December, 2028 | $87.68 | $87.54 | $97.68 | +24.20% |
Biomarin Pharmaceutical Inc Stock (BMRN) Price Forecast for 2029
The 2029 price forecast for Biomarin Pharmaceutical Inc Stock (BMRN) is $88.79 on average, with a high prediction of $100.56 and a low estimate of $77.02. This represents an +25.77% increase from the previous price of $70.60.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $88.93 | $84.85 | $89.58 | +25.97% |
| February, 2029 | $94.64 | $85.65 | $95.07 | +34.05% |
| March, 2029 | $89.16 | $88.02 | $96.13 | +26.29% |
| April, 2029 | $87.34 | $86.15 | $91.77 | +23.71% |
| May, 2029 | $84.98 | $77.02 | $88.12 | +20.37% |
| June, 2029 | $93.42 | $83.55 | $93.50 | +32.33% |
| July, 2029 | $97.42 | $93.24 | $100.56 | +37.99% |
| August, 2029 | $89.08 | $88.63 | $100.25 | +26.18% |
| September, 2029 | $92.24 | $86.60 | $95.15 | +30.66% |
| October, 2029 | $86.13 | $84.44 | $93.16 | +22.00% |
| November, 2029 | $89.63 | $85.70 | $94.36 | +26.96% |
| December, 2029 | $84.32 | $81.50 | $94.02 | +19.44% |
Biomarin Pharmaceutical Inc Stock (BMRN) Price Forecast for 2030
Biomarin Pharmaceutical Inc Stock (BMRN) is expected to reach an average price of $81.98 in 2030, with a high forecast of $99.09 and a low forecast of $64.87. This signifies an +16.11% surge from the last price of $70.60.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $82.98 | $81.81 | $92.39 | +17.53% |
| February, 2030 | $85.00 | $81.40 | $90.07 | +20.40% |
| March, 2030 | $79.66 | $78.08 | $86.12 | +12.83% |
| April, 2030 | $76.78 | $73.52 | $80.73 | +8.75% |
| May, 2030 | $69.39 | $69.34 | $79.09 | -1.72% |
| June, 2030 | $73.18 | $64.87 | $73.53 | +3.65% |
| July, 2030 | $79.69 | $72.79 | $81.16 | +12.87% |
| August, 2030 | $86.54 | $80.03 | $87.48 | +22.57% |
| September, 2030 | $93.23 | $84.81 | $95.13 | +32.06% |
| October, 2030 | $90.97 | $83.77 | $92.22 | +28.85% |
| November, 2030 | $84.66 | $78.99 | $99.09 | +19.91% |
| December, 2030 | $85.63 | $70.24 | $89.24 | +21.29% |
1.39%
0.55%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):